Clinical Considerations for the Integration of Adjuvant Olaparib into Practice for Early Breast Cancer: A Canadian Perspective

With the recent Health Canada approval of olaparib for high-risk, HER2-negative early breast cancer, physicians are now facing the practical challenges of integrating olaparib into current management of triple-negative breast cancer (TNBC) and HR-positive, HER2-negative (HR+/HER2−) early breast canc...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2023-08, Vol.30 (8), p.7672-7691
Main Authors: Henning, Jan-Willem, Boileau, Jean-François, Peck, Larissa, McFarlane, Tom
Format: Article
Language:English
Subjects:
adjuvant therapy
BRCA
Breast cancer
capecitabine
Care and treatment
early-stage breast cancer
genetic testing
olaparib
Opinion
Pharmaceutical industry
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the recent Health Canada approval of olaparib for high-risk, HER2-negative early breast cancer, physicians are now facing the practical challenges of integrating olaparib into current management of triple-negative breast cancer (TNBC) and HR-positive, HER2-negative (HR+/HER2−) early breast cancer. This review provides perspectives on some of the challenges related to identification of olaparib candidates, with a focus on the latest guidance for germline BRCA testing and considerations regarding high-risk disease definitions. Updated treatment pathways are explored for both disease states, including other adjuvant treatment options such as pembrolizumab, capecitabine, and abemaciclib. Gaps in the current literature regarding the sequential or combined use of these adjuvant therapies are noted and future, potentially informative, studies are briefly examined.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol30080556